Immune Therapeutics Inc  (IMUN)
Other Ticker:  


Immune Therapeutics Inc

IMUN's Financial Statements and Analysis

Immune Therapeutics Inc reported III. Quarter net loss per share of $-0.04 compare to earnings per share of $0.24 in the same quarter a year ago a decrease from $0.23 eps realized in II. Quarter (Jun 30 2022).

III. Quarter
Earnings Per Share Revenues
$ -0.04 $  0 Mill
$-0.28     Unch.    

Immune Therapeutics Inc's Revenue fell by 0 % in III. Quarter (Sep 30 2022) year on year, to $0 million and declined by sequentially.

Immune Therapeutics Inc is Expected to report next financial results on March 17, 2023.

More on IMUN's Income Statement

Immune Therapeutics Inc's in III. Quarter recorded net loss of $-2.493 million, compare to net income of $3.113 million achieved in III. Quarter a year ago.

Sequentially company realized net loss, compare to net income of $1.793 million in previous quarter.

More on IMUN's Growth

In III. Quarter company's net cash and cash equivalents decreased by $0 million

Immune Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Immune Therapeutics Inc payed $ -0.02 cash per share, on a free-cash flow basis .